Anti-Ion Channel Antibody Production Service

Ion channels are an important class of membrane protein. Much of normal cell physiology — and much of the pathology of disease — works through changes in channel conformation, which makes these proteins prominent drug targets. Small-molecule modulators of ion channels are well established, and antibodies that bind a channel specifically and efficiently have likewise been explored as a therapeutic approach. Developing them, however, is not straightforward.

The main obstacle is the antigen itself. An ion channel protein used as an immunogen is difficult to express and purify, so it is hard to prepare enough material to immunize with — and beyond the immunization dose, downstream screening also consumes large amounts of antigen, putting heavy pressure on how much can be produced. To address this, we maintain three dedicated ion channel antigen-production systems, matched to the target and the amount of material the project needs.

Figure 1. Extracellular antibody-mediated control of ion channels. (Source: Colecraft HM, et al. 2022)

What the Service Covers

• Antigen-production route selection – choosing among three systems according to the target and the required quantity.
• Expression and purification – producing the ion channel protein in a form that keeps it stable and correctly folded.
• Immunization – raising the response using the produced antigen.
• Screening support – supplying enough antigen for downstream selection.
• Validation – confirming the antibody against the target in the intended application.

Why Ion Channel Antigens Are Hard

Three Antigen-Production Systems

• Whole-cell expression system – a cell-based membrane protein platform in which recombinant plasmids carrying the target are introduced into host cells. A diverse set of hosts — bacterial, yeast, insect, and mammalian — supports a one-stop service that can begin at any downstream stage, from vector construction through expression, purification, and stabilization to membrane protein crystallization. Novel reagents developed to limit degradation and preserve full length, native conformation, and maximum biological activity let the route be optimized for different targets. The resulting protein supports downstream antibody screening, drug discovery, structure determination, and functional studies.
• Cell-free expression system – an in vitro protein synthesis system, such as ribosome-based display, that mimics the cell's translation machinery while using a purpose-designed liposome membrane in place of a cell membrane, so the newly made protein is inserted into the membrane and keeps its native conformation and activity. Its advantages include high purity, speed, stability, high yield, and reproducibility, and most importantly it bypasses host toxicity and cellular limits. It is readily adapted to specific requirements, such as liposome size and modification, or loading therapeutic agents inside the liposome as microcapsules. Available strategies include bacterial extract, wheat germ, baculovirus, and rabbit reticulocyte systems.
• Virus-like particle / display system – virus-like particles are artificial nanostructures made by modifying a viral genome so it expresses the target protein. A VLP keeps a virus's self-assembly behavior but loses its infectivity. The gene for a viral structural protein and the gene for the target are fused by molecular biology and introduced into a suitable host, and the resulting chimeric protein assembles automatically into a particle that displays the target on its coat.

Workflow

• Assess the target – define the ion channel and the quantity of antigen the project needs.
• Choose a production system – whole-cell, cell-free, or virus-like particle, according to the target.
• Produce and confirm the antigen – generate the protein and verify its stability and conformation.
• Immunize and screen – raise the response and select channel-specific candidates.
• Validate and deliver – confirm performance and supply the antibody with data.

Why Work With Us

For ion channels the binding constraint is usually antigen supply, so we solve that first. Three independent production systems — whole-cell expression, cell-free synthesis, and virus-like particle display — let us match the method to the target and produce enough material for immunization and screening while protecting the protein's full length, native fold, and activity. This turns the hardest part of an ion channel antibody project from a bottleneck into a managed step.